Skip navi

News

Learn what's new with KOLON Pharma.

Kolon Pharma obtained ISO37001 certification for the first among mid-sized pharmaceutical companies.

Kolon Pharma obtained ISO37001 certification for the first among mid-sized pharmaceutical companies.

Kolon Pharma announced on 11th April that it obtained ISO37001 certification, the international standard for anti-bribery management systems, from the Korea Compliance Certification Assurance on 6th April. Lee Won-ki, director of the Korea Compliance Certification Assurance, visited Kolon Pharma and awarded ISO37001 certification in person.   ISO37001 was introduced in October 2016 as a standardization of policies and procedures for planning, operation, evaluation and improvement by International Organization for Standardization (ISO) to prevent the possibility of bribery in the organization. It was introduced in Korea last April.   The pharmaceutical industry has decided to push forward ISO37001 certification in order to eradicate the drug rebates, which has become a social problem. Kolon Pharma obtained ISO37001 for the third following Hanmi Pharm and Yuhan. This is the first among mid-sized pharmaceutical companies. Kolon Pharma was not an eight company of board directors designated by the Korean Pharmaceutical and Bio-Pharma Manufactures Association as the primary certification target, but has voluntarily applied for certification. In order to obtain ISO37001 certification, Kolon Pharm has set up the policies and procedures to prevent risks after diagnosing internal and external risks of bribery that can occur throughout the entire company. In addition, Kolon Pharma has established effective anti-bribery management system and evaluated performance through declaring policies to eradicate bribery, fostering internal assessors, establishing goals to prevent bribery, and preparing ethical management documents of executives and employees. In addition, Lee Woo-suk, CEO of Kolon Pharma, has set his management goal this year for effective system of ISO37001. He said, "We will do our best to become a competitive company by practicing ethical management with ISO37001 certification at the present time when society's demand for ethical management of corporations is growing."   Kolon Pharma received ‘A grade’ in the rating test of Compliance Program (CP) last year along with ISO37001 certification. <A Photo by KOLON Pharma Co., Ltd.>

  • 2018.04.11
  • Hit. 8
Kolon Life Sciences selected Mundipharma and Kolon Pharma as partners of ‘INVOSSA’

Kolon Life Sciences selected Mundipharma and Kolon Pharma as partners of ‘INVOSSA’

Kolon Life Science announced on 29th March that it has selected two companies, Mundipharma and Kolon Pharma, as the domestic marketing and sales strategic partners of ‘Invossa (Ingredient name: tonogenconcel)’ which is the first cell gene therapy product in the world. Under the terms of the partnership, Mundipharma will be responsible for the marketing and distribution of Invossa to general and semi-private hospitals, while Kolon Pharma will take responsibility for the general practitioner market. Invossa is the first therapy product of degenerative arthritis in the world that can simultaneously provide improvement effects of pain and function/joint structure, unlike conventional methods of surgery or drug treatment.   It is evaluated as a bio-new-drug product of ‘first-in-class’ with innovative technology that has demonstrated sustained pain reduction and functional improvement of articular joint for two years following a single injection in clinical trials.   In July last year, it has completed the application for approval to the Korea Food and Drug Administration(KFDA) and plans to complete the approval within the second quarter of this year. Through the partnership with Mundipharma and Kolon Pharma, it plan to launch the product in Korea and carry out marketing activities. Mundipharma is evaluated as an American company with the best sales network and marketing ability in neurosurgery, anesthesia, and other department, mainly orthopedic surgery. Especially, it has influence in the area of orthopedics in Korea through pain treatment and wet dressing. The number of patients with degenerative arthritis in the Korea is around 5 million. The company estimates that the market potential will be huge given that 2~3 level of patients with degenerative arthritis, which can be treated with Invossa, are around 2 million. Lee Woo-suk, CEO of Kolon Life Science, said, “The process for Invossa is shaping up well through the contracts with leading partners such as Mundipharma and Mitsubishi Tanabe Pharma, which are global top pharmaceutical companies, in sales, marketing, technology, clinical and so on.” Also, he said, “Through this, it will be able to launch successfully in Korea and become a global new drug." <A Photo by KOLON Pharma Co., Ltd.>

  • 2017.03.30
  • Hit. 13
Foster® has approved for COPD!

Foster® has approved for COPD!

"Foster is a fixed combination of beclomethasone dipropionate (corticosteroid) and formoterol fumarate (a long-acting β2-agonist with rapid onset of effect) to be taken by inhalation. In 2006 the drug was approved for the maintenance therapy of asthma; after its first launch in Germany on October 2006, it is now sold in over 35 countries worldwide, including Russia and China. Further launches are planned throughout 2014. Foster is also available as a DPI ( Dry Powder Inhaler, in NEXThaler device) in the asthma indication. Foster’s key feature is its extra-fine formulation, which guarantees the uniform distribution and high drug deposition throughout the entire bronchial tree, including the small airways. In 2013, Foster pMDI obtained the approval of the MART (Maintenance And Reliever Therapy) posology and the approval of COPD indication is another important achievement for this product. With the new approval in COPD, Foster pMDI is achieving a broader therapeutic indication in patients with obstructive respiratory disorders and it is expected to become one of the recommended inhalation options in this steadily increasing population of patients."  Foster®, representative ethical drug of Kolonpharma, has approaved for COPD in 1st Sep 2015. Foster® has gained permission to be prescribed if FEV1 indicates lower than 60%. The guideline of KATRD(The Korean Academy of Tuberculosis and Respiratory Diseases) for COPD treatment also recommends ICS/LABA combination drug  in cases that FEV1 goes to lower than 60% of normal condition or if there were more than 2 cases of acute exacerbation in the past a year. Foster® is a fixed combination of beclomethasone dipropionate (corticosteroid) and formoterol fumarate (a long-acting β2-agonist with rapid onset of effect) to be taken by inhalation.

  • 2015.12.11
  • Hit. 166
Bicogreen S Tab., 'To You Who Never Changes': Announcement of the Selected Work of the Public Copy Contribution for the New Package

Bicogreen S Tab., 'To You Who Never Changes': Announcement of the Selected Work of the Public Copy Contribution for the New Package

With the successful completion of 'The Public Copy Contribution for the New Package of Bicogreen S Tab.' by KOLON Pharma from last June 8th to June 26th for 19 days holding about 7000 participants, the selected work was announced.      In the public copy contribution for the new package through Bicogreen S Facebook, 'To You Who Never Changes' by Seung-won Na* won the grand prize through the final screening. 'Who Told You No News are Good News?' won the highest work award, and the outstanding work was 'Good Night while Eating, and Good Morning When Digested.' According to the panel of judges they "selected the works based on the applicability of whether the copy expressed the ambiguous words which the real sufferers from constipation can sympathize with, and the attempt at marketing with Facebook and the public contribution as the strategy of marketing working in both directions with the consumers was new and effective." The prize money of 2 million KRW will be given to the grand prize winner of the public contribution, 'To You Who Never Changes,' and 1 million KRW to the highest work award and 500,000 KRW for the outstanding award will be delivered. Also, the set gifts will be given to the winners of the 50 participants' awards and the selected 3 copies will be used as the package copies of Bicogreen S Tab. and again in the theater advertisement during July and August along with the bus advertisement in the regions of Seoul · Gyeonggi. They stated that from now on the consistent communication with the consumers through Bicogreen S Tab. Facebook (www.facebook.com/bicogreens) will be continued such as diverse public contribution and events where the consumers participate. Bicogreen S Tab. promotes the peristalsis of the colon from the outset by regulating the breaking down speed in the intestines rapidly, and manifests an effect in 7~8 hours of internal application. It is developed as the smallest tablet among the domestic constipation medicines for handy carrying.

  • 2015.07.03
  • Hit. 105
<< <12>>>
top